Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Enrollment concludes in TAXUS V study

April 7, 2004

CV Therapeutics claims adenosine A1 agonists with antiarrhythmic and antilipolytic activity

April 6, 2004

GlaxoSmithKline advances new Lp-PLA2 inhibitor into the clinic

April 5, 2004

Enrollment completed in phase II trial of Liprostin for PVD

April 5, 2004

Japanese approval for Cypher sirolimus-eluting coronary stent

April 5, 2004

Intravenous Remodulin sNDA accepted for review

April 2, 2004

Enrollment completed in phase II study of Deltavasc for PAD

April 1, 2004

CV Therapeutics seeks European approval of ranolazine for chronic angina

April 1, 2004

Second phase III study of RSD-1235 in atrial fibrillation commences

April 1, 2004

Enrollment completed in PISCES study of Medstent

March 31, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...